Study The Principles Of Recombinant Human Glucagon Like Peptide-1 (7-36) On Reducing The Glucose In The Bloodstream

rhGLP-1 (7-36) was produced by Shanghai huayi bio-lab limited company, which obtained the multi-peptides with the genetic engineering way. During the gene recombination GLP-1 (1-37)'s 7 to 36 amino acid sequences was retained which decided the bio-activity. The study of rhGLP-1 (7-36)'s activity was based on GLP-1 (1-37)'s. The research had two aspects: cell experiments and animal experiments. In cell experiments portion, first, we screened the sensitive cells and built up the cell mode. Second, we studied the effection of rhGLP-1 (7-36) on the expression of insulin by P-cell and the relationship between the amount of rhGLP-1 (7-36) and insulin. Third, the effection of glucose during the process. In the animal portion, we studied the effection of rhGLP-1 (7-36) on reducing the glucose in the bloodstream through four animal models.The research proved that rhGLP-1 (7-36) could promote beta cell to express the cAMP and the insulin, that kind of function was the glucose dependence, in certain glucose density scope, increasing the amount of rhGLP-1 (7-36) along with the insulin density increasing. Though the normal glucose animal model, the high glucose animal model, the glucose tolerance animal model, and the chemical broken animal model, the research proved that rhGLP-1 (7-36) can reduce the high glucose, but will not cause the low glucose. It is safe reliable. The testing method of rhGLP-1 (7-36)'s bio-activity was built up, including the cell testing method and the animal testing method, which is up to the standard t totally.